Monoclonal Anti-Adenoviruses AAV9 Neutralizing Antibody, Mouse IgG1 (28B9C5)

Customer Reviews
Cat. No. / Size
Price
Qty
AA9-Y2142-100ug
$400.00
AA9-Y2142-1mg
$2770.00
ETA of in-stock products:2 business days

Product Details

  • Source

    Monoclonal Anti-Adenoviruses AAV9 Neutralizing Antibody, Mouse IgG1 (28B9C5) is a mouse monoclonal antibody derived from hybridoma cells fused with SP2/0 myeloma cells and murine B lymphocytes.

  • Antibody Type

    Hybridoma Monoclonal

  • Clone

    28B9C5

  • Isotype

    Mouse IgG1, Kappa

  • Host Species

    Mouse

  • Immunogen

    AAV9

  • Application

    Application
    Recommended Usage
    ELISA
    0.2-2 μg/mL
  • Cross Verification

    This product can specially react with AAV9.
    No reactivity to AAV1/ AAV2/ AAV3/ AAV5/ AAV6/ AAV8.

  • Purification

    Protein A purified / Protein G purified.

  • Concentration

    Please refer to the Certificate of Analysis (CoA).

  • Form

    Liquid

  • Formulation

    Supplied a 0.22 μm-filtered solution in PBS (pH 7.4), with trehalose as protectant.

    Please contact us for customized product forms or formulations.

  • Storage

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. The product MUST be stored at -70°C or lower upon receipt;
    2. -70°C for 12 months under sterile conditions.
  • Notices

    Product Specific Notices: For research use only.

  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Customers Also Viewed

Performance Data

  • Bioactivity-ELISA

     AAV9 ELISA

    Immobilized AAV9 at 1E+10capsids/ml (100 μl/well) can bind Monoclonal Anti-Adenoviruses AAV9 Neutralizing Antibody, Mouse IgG1 (28B9C5) (Cat. No. AA9-Y2142) with a linear range of 0.50-30ng/mL (QC tested).

    Protocol

Customer Reviews
Writing Reviews

Background

AAV9 (Adeno-Associated Virus Serotype 9) is a highly efficient and safe gene therapy vector belonging to the Parvoviridae family. It is characterized by broad tissue tropism, enabling efficient transduction of the heart, liver, skeletal muscle, central nervous system (with the ability to cross the blood-brain barrier), and retina, among others. Compared to other serotypes, AAV9 exhibits stronger systemic diffusion capacity and lower immunogenicity, reducing the risk of host immune rejection. Its single-stranded DNA genome (~4.7 kb) allows long-term stable expression of transgenes but has a limited packaging capacity (≤5 kb).
AAV9 has been utilized in clinical trials for various diseases, such as spinal muscular atrophy (SMA), Duchenne muscular dystrophy (DMD), and familial hypercholesterolemia.

Recent Advances

 
Contact Us
Drug Candidate Licensing
More
  • Basic Product Information
  • Product Details
  • Customers Also Viewed
  • Performance Data
  • Customer Reviews
  • Background
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland